Generic Name and Formulations:
Cefditoren (as pivoxil) 200mg, 400mg; tabs.
Vansen Pharma Inc.
Indications for SPECTRACEF:
Susceptible mild to moderate acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia (CAP), pharyngitis/tonsillitis, uncomplicated skin and skin structure infections.
Take with meals. Bronchitis: 400mg twice daily for 10 days. CAP: 400mg twice daily for 14 days. Pharyngitis/tonsillitis, skin and skin structure: 200mg twice daily for 10 days. Renal impairment (CrCl 30–49mL/min): max 200mg twice daily; CrCl <30mL/min: max 200mg once daily; ESRD: not established.
Milk protein allergy (not lactose intolerance). Carnitine deficiency or conditions causing carnitine deficiency.
Penicillin or other allergy. Not for long-term therapy. Decreased muscle mass (risk of carnitine deficiency). Monitor prothrombin time in renal or hepatic impairment or poor nutritional state. Labor & delivery. Pregnancy (Cat.B). Nursing mothers.
Avoid drugs that reduce gastric acidity. Potentiated by probenecid. May cause false (+) glucose test with Clinitest, Fehling's or Benedict's soln, Coomb's test; false (–) with ferricyanide test.
GI upset, headache, transient reduction in plasma carnitine levels; pseudomembranous colitis.
Tabs (200mg)—20-count blister pack; 400mg—2-, 20-, 28-count blister pack
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma
- CLL: Venetoclax Plus Rituximab Improves 2-Year PFS
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma